Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy

NCT06003881 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

CD55-Deficient Protein-Losing Enteropathy

Interventions

DRUG: Pozelimab

Sponsor

Regeneron Pharmaceuticals